Last Updated: September 24, 2026

Sulfur - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for sulfur and what is the scope of freedom to operate?

Sulfur is the generic ingredient in two branded drugs marketed by Poythress and Bracco, and is included in two NDAs. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Summary for sulfur
US Patents:3
Tradenames:2
Applicants:2
NDAs:2
Raw Ingredient (Bulk) Api Vendors: 37
Clinical Trials: 82
DailyMed Link:sulfur at DailyMed
Recent Clinical Trials for sulfur

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Children's Hospital of PhiladelphiaPHASE2
Al-Mustansiriyah UniversityNA
john eisenbreyPHASE2

See all sulfur clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for sulfur
D10AB Preparations containing sulfur
D10A ANTI-ACNE PREPARATIONS FOR TOPICAL USE
D10 ANTI-ACNE PREPARATIONS
D Dermatologicals

US Patents and Regulatory Information for sulfur

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bracco LUMASON sulfur hexafluoride lipid-type a microspheres FOR SUSPENSION;INTRAVENOUS 203684-001 Oct 15, 2014 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Bracco LUMASON sulfur hexafluoride lipid-type a microspheres FOR SUSPENSION;INTRAVENOUS 203684-001 Oct 15, 2014 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Bracco LUMASON sulfur hexafluoride lipid-type a microspheres FOR SUSPENSION;INTRAVENOUS 203684-001 Oct 15, 2014 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Poythress BENSULFOID sulfur POWDER;TOPICAL 002918-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Subscribe to access the full database, or Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links